PMDI · Psychemedics Corp
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 4, 2024; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMDI
this stock
Psychemedics Corp
|
$15.21M | +55.6% | +1.8% | — | 0.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$230.05B | +6.5% | +14.5% | 33.5 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.09B | -6.7% | +8.5% | 37.1 | 1.2% |
|
NTRA
Natera, Inc.
|
$47.03B | +40.5% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.72B | -17.7% | +10.4% | 39.0 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 4, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMDI | +12.2% | +24.5% | +10.7% | +3.8% | +55.6% |
| SPY | -2.4% | -3.4% | +6.7% | -3.6% | +6.9% |
| vs SPY | +14.5% | +27.9% | +4.0% | +7.4% | +48.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.